JPWO2023051802A5 - - Google Patents

Info

Publication number
JPWO2023051802A5
JPWO2023051802A5 JP2024519557A JP2024519557A JPWO2023051802A5 JP WO2023051802 A5 JPWO2023051802 A5 JP WO2023051802A5 JP 2024519557 A JP2024519557 A JP 2024519557A JP 2024519557 A JP2024519557 A JP 2024519557A JP WO2023051802 A5 JPWO2023051802 A5 JP WO2023051802A5
Authority
JP
Japan
Prior art keywords
rest
cells
neurons
variant
glial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024534667A (ja
Publication date
Priority claimed from CN202111158620.4A external-priority patent/CN115887655B/zh
Application filed filed Critical
Publication of JP2024534667A publication Critical patent/JP2024534667A/ja
Publication of JPWO2023051802A5 publication Critical patent/JPWO2023051802A5/ja
Pending legal-status Critical Current

Links

JP2024519557A 2021-09-30 2022-09-30 神経系疾患の直接分化転換治療 Pending JP2024534667A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111158620.4 2021-09-30
CN202111158620.4A CN115887655B (zh) 2021-09-30 2021-09-30 直接转分化治疗神经系统疾病
PCT/CN2022/123409 WO2023051802A1 (zh) 2021-09-30 2022-09-30 直接转分化治疗神经系统疾病

Publications (2)

Publication Number Publication Date
JP2024534667A JP2024534667A (ja) 2024-09-20
JPWO2023051802A5 true JPWO2023051802A5 (enExample) 2025-10-08

Family

ID=85750328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519557A Pending JP2024534667A (ja) 2021-09-30 2022-09-30 神経系疾患の直接分化転換治療

Country Status (8)

Country Link
US (1) US20250115650A1 (enExample)
EP (1) EP4410296A4 (enExample)
JP (1) JP2024534667A (enExample)
KR (1) KR20240082366A (enExample)
CN (3) CN115887655B (enExample)
AU (1) AU2022357103A1 (enExample)
CA (1) CA3233534A1 (enExample)
WO (1) WO2023051802A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024199511A1 (zh) * 2023-03-30 2024-10-03 上海鲸奇生物科技有限公司 治疗神经系统疾病的表达载体和组合物
WO2025173411A1 (ja) * 2024-02-14 2025-08-21 国立大学法人筑波大学 網膜神経節細胞分化誘導用キット、医薬組成物及び緑内障モデル

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2774698B1 (fr) * 1998-02-12 2002-03-01 Rhone Poulenc Rorer Sa Utilisation d'elements de regulation negative pour l'expression neurospecifique de transgenes
ITVA20060041A1 (it) * 2006-07-05 2008-01-06 Dialectica Srl Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington
CA2704314A1 (en) * 2007-11-02 2009-05-07 Nederlands Instituut Voor Neurowetenschappen Polypeptides involved in neuronal regeneration-associated gene expression
WO2011099502A1 (ja) * 2010-02-10 2011-08-18 公立大学法人横浜市立大学 神経選択的転写抑制因子NRSFに特異的に結合するmSin3B に結合する化合物の利用
US20150299698A1 (en) * 2012-11-01 2015-10-22 The Regents Of The University Of California Methods for engineering non-neuronal cells into neurons and using newly engineered neurons to treat neurodegenerative diseases
US20160031958A1 (en) * 2014-08-01 2016-02-04 Oregon Health & Science University Methods and compositions useful in manipulating the stability of re1 silencing transcription factor
CA3062995A1 (en) * 2017-05-12 2018-11-15 New York Stem Cell Foundation, Inc. Systems
GB202017810D0 (en) * 2018-04-11 2020-12-23 Univ California Reprogramming of non-neuronal cells into neurons and methods and compositions to treat neurodegenerative diseases and disorders
CA3103663A1 (en) * 2018-06-18 2019-12-26 University Of Rochester Inhibition of re1-silencing transcription factor in the treatment of schizophrenia and other neuropsychiatric disorders
IL293165A (en) * 2019-11-22 2022-07-01 Alcamena Stem Cell Therapeutics Llc Compositions and methods for silencing transcription factor re1 target genes

Similar Documents

Publication Publication Date Title
CA2165969A1 (en) Vertebrate apoptosis gene: compositions and methods
CN112386699A (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
CN112451669A (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
US20250115650A1 (en) Direct transdifferentiation for treatment of neurological disease
CA3197321A1 (en) Neurod1 vector
JP7680072B2 (ja) リプログラミング用機能性断片、組み合わせ、およびその用途
WO2021032068A1 (zh) Ptbp1抑制剂在预防和/或治疗功能性神经元死亡相关的神经系统疾病中的应用
US20250281648A1 (en) Use of transdifferentiation of glial cells into neurons in prevention or treatment of diseases associated with neuron loss-of-function or death
JPWO2023051802A5 (enExample)
IL301750A (en) Neurod1 and dlx2 vector
KR102594254B1 (ko) 운동성 신경세포 직접교차 분화용 인자
JP7620338B2 (ja) 機能性ニューロンへのグリア細胞の分化転換を誘導するためのＮｅｕｒｏｇ２機能性断片送達システム、宿主細胞及び医薬組成物
TWI910717B (zh) 一種胜肽拓印轉染複合物及其用途與製備方法、以及利用胜肽拓印轉染複合物誘導細胞分化為神經細胞之方法
CN115335525B (zh) 经修饰的通道视紫红质
JPWO2022052964A5 (enExample)
US20240400984A1 (en) Treatment of Neuronal Absence Disease by Transdifferentiating Treatment
Breejen Overview of Delivery Technologies for Molecular Determinants in Neuronal Reprogramming
CN120958137A (zh) 治疗神经系统疾病的表达载体和组合物
Mitroshina et al. Application of the AAV-Syn-BDNF-EGFP Virus Vector as a Neuroprotective Agent in Modeling Hypoxia in vitro
WO2025264696A2 (en) Restorative cell therapy for eye diseases and vision loss
CN120093951A (zh) 一种利用内源性小胶质细胞再生视网膜神经节细胞的组合物及应用
KR20250097002A (ko) Oct4, Sox2, Klf4 단백질을 포함하는 엔지니어링된 바이러스-유사 입자를 유효성분으로 포함하는 노화의 예방 또는 치료용 약제학적 조성물
HK40097397A (en) Functional fragment for reprogramming, composition, and application thereof
CN116670160A (zh) Dlx2载体
CN116761812A (zh) Neurod1和dlx2载体